

ANUH PHARMA LIMITED

CIN : L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; email: anuh@sk1932.com;

Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30, 2017

(₹ in Lakhs except EPS)

Sr. No.	Particulars	3 months ended	Corresponding
		30/06/2017	3 months ended in the previous year
		Unaudited	Unaudited
1	Revenue from operations (Gross of Excise)	5,483.40	5,172.74
2	Net Profit /(loss) for the period (before tax, Exceptional and /or Extra ordinary items)	702.19	530.14
3	Net Profit /(loss) for the period before tax (after Exceptional and /or Extra ordinary items)	702.19	530.14
4	Net Profit /(loss) for the period after tax (after Exceptional and /or Extra ordinary items)	560.19	389.14
5	Total Comprehensive Income for the period [(comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)]	631.62	473.70
6	Paid up Equity Share Capital (Face value of ₹ 5/- each)	1,252.80	1,252.80
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-
	Earnings per equity share (of ₹ 5/- each) (for continuing operations and discontinued operations) (Non annualised) (In Rs.)		
	(a) Basic	2.52	1.89
	(b) Diluted	2.52	1.89

Notes :

- The above financial results for the quarter ended on June 30, 2017 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their Meeting held on September 08, 2017. The Statutory Auditors has carried out a limited review of the results for the quarter ended on June 30, 2017.
- The Company has adopted Ind-AS from April 01, 2017 with a transition date of April 01, 2016 and accordingly this financial results have been prepared in accordance with the Ind-AS prescribed under section 133 of Companies Act, 2013. Consequently, the results for the quarter ended on June 30, 2016 have been restated to comply with Ind-AS. The reconciliation of Net Profit reported under previous IGAAP and restated Ind-AS is as under:

Particulars	Quarter Ended 30.06.2016 Unaudited (₹. In Lakhs)
Net profit as per previous IGAAP	389.14
Other Comprehensive Income (Net of tax)	
Add: Impact of measuring Investments at fair value	84.57
Total Comprehensive Income as per Ind-AS	473.70

- The figures for the quarter ended on June 30, 2016 are Ind-AS compliant, but were not subject to limited review or audit. However, the management of the Company has exercised due diligence to ensure that the financial results provide a true and fair view of the Company's affairs.
- The above is an extract of the detailed format of financial results for the quarter ended on June 30, 2017, filed with the Stock Exchange as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the quarter ended on June 30, 2017 is available on the Stock Exchange website viz . www.bseindia.com and on the Company's website i.e. www.anuhpharma.com.
- Corresponding figures of the previous quarters have been regrouped, to make them comparable wherever necessary.
- The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".

For Anuh Pharma Limited
Sd/-

Bipin N. Shah

Managing Director

(DIN: 00083244)

Place : Mumbai

Date : September 08, 2017